Core Viewpoint - Huaxia Eye Hospital's stock price has declined significantly since its IPO, currently trading at 20.72 yuan, representing a drop of 2.95% and indicating a state of underperformance since its initial offering price of 50.88 yuan [1] Group 1: IPO and Financial Performance - Huaxia Eye Hospital was listed on the Shenzhen Stock Exchange's ChiNext board on November 7, 2022, with an initial offering price of 50.88 yuan per share [1] - The total funds raised from the IPO amounted to 305.28 million yuan, with a net amount of 276.85 million yuan after deducting issuance costs [1] - The final amount raised exceeded the original plan by 198.99 million yuan, which was initially set at 77.85 million yuan for various projects [1] Group 2: Use of Proceeds - The funds raised are intended for several projects, including the Tianjin Huaxia Eye Hospital project, regional vision center construction, upgrading existing medical service capabilities, information management system development, and supplementing operational funds [1] Group 3: Dividend Distribution - On July 4, 2023, Huaxia Eye Hospital announced a cash dividend of 2.8 yuan per 10 shares, totaling 15.68 million yuan, based on a total share capital of 56 million shares as of December 31, 2022 [2] - Additionally, the company will increase its share capital by 5 shares for every 10 shares held, raising the total share capital from 56 million to 84 million shares [2]

Company Overview - Huaxia Eye Hospital (SZ 301267) announced an investor research meeting scheduled for September 16, 2025, where the company’s board secretary and securities representatives will address investor inquiries [1] Financial Performance - For the first half of 2025, Huaxia Eye Hospital's revenue composition is as follows: Refractive services account for 36.9%, comprehensive optometry projects for 24.04%, cataract services for 20.14%, posterior segment projects for 12.94%, and other services for 5.99% [1] - As of the report date, Huaxia Eye Hospital has a market capitalization of 17.9 billion yuan [1]

Group 1: Business Overview - The company's current medical insurance business accounts for a low proportion of overall revenue, with ongoing reforms in payment methods and centralized procurement policies impacting short-term performance [2][3] - The company has identified 24 key investment provinces for future expansion, utilizing both self-built and acquisition strategies to establish a network of ophthalmic medical services [3][4] Group 2: Revenue Structure - In the first half of 2025, the revenue breakdown is as follows: Refractive business at 36.90%, Vision care at 24.04%, Cataract business at 20.14%, and Posterior segment business at 12.94% [4] Group 3: Market Trends - The aging population is driving long-term demand for age-related eye diseases, while the national strategy for myopia prevention remains a challenge for children and adolescents [5] - The penetration rate of eye disease diagnosis in China is still low compared to developed countries, indicating significant market potential for the ophthalmic medical service industry [5] Group 4: Technological Advancements - The company is collaborating with smart hardware firms to explore the application potential of AI glasses in ophthalmic medical services [6][7] - Multiple smart medical platforms have been established to enhance diagnostic and treatment services, including the Eye Tong Smart Diagnosis Service Platform 3.0 and a 5G remote diagnosis platform [7]

上海市锦天城律师事务所 关于华厦眼科医院集团股份有限公司 2025 年第一次临时股东会的 上海市锦天城律师事务所 关于华厦眼科医院集团股份有限公司 2025 年第一次临时股东会的 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 法律意见书 致：华厦眼科医院集团股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受华厦眼科医院集团股份有 限公司（以下简称"公司"）委托，就公司召开 2025 年第一次临时股东会（以 下简称"本次股东会"）的有关事宜，根据《中华人民共和国公司法》（以下简 称"《公司法》"）《上市公司股东会规则》等法律、法规、规章和其他规范性文 件以及《华厦眼科医院集团股份有限公司章程》（以下简称"《公司章程》"） 的有关规定，出具本法律意见书。 上海市锦天城律师事务所 法律意见书 一、 本次股东会召集人资格及召集、召开的程序 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则 ...

证券代码：301267 证券简称：华厦眼科 公告编号：2025-030 1、本次股东会不存在否决议案的情形。 2、本次股东会不涉及变更前次股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、股东会届次：2025 年第一次临时股东会。 2、会议召开时间 2025年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 华厦眼科医院集团股份有限公司 7、本次会议的召集、召开符合有关法律、行政法规、部门规章、规范性文 件和《公司章程》的规定。 （二）会议出席情况 1、通过现场和网络投票的股东 111 人，代表股份 675,792,277 股，占公司有 表决权股份总数的 81.1790%。 （1）现场会议时间：2025 年 9 月 10 日下午 15:00； （2）网络投票时间：2025 年 9 月 10 日； 通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 9 月 10 日 9:15-9:25、9:30-11:30 和 13:00-15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为：202 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [6] Core Insights - The company reported a revenue of 2.139 billion yuan for H1 2025, representing a year-over-year increase of 4.31%, and a net profit attributable to shareholders of 282 million yuan, up 6.20% year-over-year [4][10] - The introduction of new surgical techniques has significantly boosted the company's refractive business, leading to a revenue of 789 million yuan in H1 2025, which is a 13.75% increase year-over-year [12] - The company has established a nationwide medical network with 64 specialized eye hospitals and 67 vision centers, enhancing its service coverage across various regions [13] Financial Performance Summary - For H1 2025, the company's gross margin was 45.20%, a slight decrease of 0.64 percentage points year-over-year, but improved in Q2 2025 to 45.44%, reflecting a recovery from previous impacts [11] - The company expects revenues for 2025-2027 to be 4.379 billion, 4.878 billion, and 5.479 billion yuan respectively, with year-over-year growth rates of 8.74%, 11.39%, and 12.32% [14] - The net profit attributable to shareholders is projected to be 570 million, 692 million, and 811 million yuan for the same period, with growth rates of 33.05%, 21.27%, and 17.21% respectively [14]

中国国际金融股份有限公司 关于华厦眼科医院集团股份有限公司 2 | 事项 | 存在的问题 | 采取的措施 | | --- | --- | --- | | 11.其他（包括经营环境、业务发 | | | | 展、财务状况、管理状况、核心 | 无 | 不适用 | | 技术等方面的重大变化情况） | | | 2025 年半年度持续督导跟踪报告 | 保荐人名称：中国国际金融股份有限公司 | 被保荐公司简称：华厦眼科 | | --- | --- | | 保荐代表人姓名：周凌轩 | 联系电话：010-65051166 | | 保荐代表人姓名：赵冀 | 联系电话：010-65051166 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 0 次 | | 2．督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不 | | | 限于防止关联方占用公司资源的制度、募集资金管 | 是 | | 理制度、内控制度、内部审计制度、关 ...

Summary of Key Points Core Viewpoint - A total of 135 stocks received buy ratings from institutions today, with 17 stocks receiving initial attention from institutions, indicating a strong interest in the market and potential investment opportunities [1]. Institutional Ratings - 140 buy rating records were published today, with 29 of these providing future target prices. 13 stocks have an upside potential exceeding 20%, with AVIC Optoelectronics showing the highest potential at 61.62% [1]. - Notable stocks with high upside potential include Noli Shares at 48.46% and United Imaging Healthcare at 37.22% [1]. - 17 stocks received initial buy ratings from institutions, including Haimeixing and Hengli Hydraulic [1]. Market Performance - Stocks rated with buy ratings saw an average increase of 3.27%, outperforming the Shanghai Composite Index. 119 stocks experienced price increases, with several hitting the daily limit up [1]. - Stocks with significant declines included Noli Shares, Agricultural Bank, and Shoufang Environmental Protection, with declines of 3.23%, 2.93%, and 1.26% respectively [1]. Industry Focus - The most favored industries include power equipment and machinery, each with 17 stocks listed in the buy rating category. The pharmaceutical and communication sectors also attracted attention, with 15 and 6 stocks respectively [2]. - Specific stocks receiving multiple buy ratings include Betaini, Kebo Da, AVIC Optoelectronics, and Yunnan Baiyao, each with two buy ratings [2][3]. Detailed Stock Information - A selection of stocks with buy ratings includes: - Betaini (2 ratings, +2.22% today, PE 40.30) in beauty care - Kebo Da (2 ratings, +10.00% today, PE 27.44) in automotive - AVIC Optoelectronics (2 ratings, +0.57% today, PE 28.83) in defense and military [2][3]. - Other notable stocks include: - Yunnan Baiyao (2 ratings, +1.06% today, PE 14.56) in pharmaceuticals - Zhonglian Heavy Industry (2 ratings, +0.41% today, PE 11.39) in machinery [2][3]. Additional Stock Ratings - Additional stocks with single buy ratings include: - Xuji Electric (1 rating, +2.09% today, PE 18.44) in power equipment - Xugong Machinery (1 rating, -0.20% today, PE 13.29) in machinery - China Rare Earth (1 rating, +2.33% today, PE 174.07) in non-ferrous metals [3][4].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][4] Core Views - The company's refractive business is experiencing good growth, leading to a stable and positive performance [1][4] - The company has achieved a revenue of 2.139 billion yuan in the first half of 2025, representing a year-on-year increase of 4.31%, and a net profit of 282 million yuan, up 6.20% year-on-year [4][5] - The company continues to expand its network of specialized eye hospitals and vision centers, with a total of 64 eye hospitals and 67 vision centers established across 19 provinces and municipalities [4][5] Summary by Sections Financial Performance - In Q2 2025, the company reported a revenue of 1.046 billion yuan, a decrease of 2.47% year-on-year, while the net profit for the same quarter was 132 million yuan, an increase of 20.73% year-on-year [4] - The gross profit margin for H1 2025 was 45.20%, a slight decrease of 0.64 percentage points year-on-year, while the net profit margin increased by 0.71 percentage points to 14.04% [4] Business Segments - The refractive segment generated revenue of 789 million yuan in H1 2025, a year-on-year increase of 13.75%, making it the main growth driver [4] - The cataract segment saw a revenue decline of 7.33% year-on-year, totaling 431 million yuan, primarily due to high base effects from the previous year [4] Growth Strategy - The company is focused on a dual strategy of "internal growth + external mergers and acquisitions," aiming to enhance its national presence in the eye care sector [4] - The company has introduced advanced surgical technologies and high-end artificial lenses to improve service quality and expand its offerings [4] Earnings Forecast - The company expects net profits of 515 million yuan, 605 million yuan, and 697 million yuan for the years 2025, 2026, and 2027, respectively, with corresponding EPS of 0.61 yuan, 0.72 yuan, and 0.83 yuan [5][6]

Core Insights - The conference held by Huaxia Eye Hospital Group focused on advancing myopia prevention strategies and enhancing service quality, aiming for high-quality development in myopia control in China [1][4][6] Group 1: Conference Highlights - The "2025 Autumn Myopia Prevention Work Promotion Conference" took place in Nanjing, gathering leaders and representatives to discuss strategies for myopia prevention [1] - The launch of the "11th National Myopia Prevention Awareness Month" and the "Multi-City Action for Children's Eye Health" initiative aims to create a nationwide public welfare platform for children's eye health services [2] - 45 hospitals were recognized for their exemplary campus screening services, receiving awards for their contributions to public welfare in myopia prevention [3] Group 2: Strategic Development - The conference emphasized the importance of internal development as a foundation for enhancing core competitiveness and service quality [4] - Group leaders outlined a transformation strategy focusing on proactive adaptation and deepening internal development to navigate market changes [4] - Key implementation points were discussed, including quality improvement in screenings, talent optimization, brand collaboration, AI technology integration, and the establishment of a "5 Action Plan" [4][5] Group 3: Innovation and Technology - The "Eye Care通" platform was showcased for its role in utilizing big data to optimize business processes and enhance service experiences [5] - The focus on adult visual management needs was highlighted, with solutions presented to bridge the gap in myopia prevention implementation [5] Group 4: Commitment and Accountability - The conference included a recognition ceremony for outstanding teams and individuals in myopia prevention, reinforcing commitment to goals through the signing of responsibility agreements [6] - A total of 15 core work consensus points were established, marking a transition from discussion to actionable execution [7]